Clovis Oncology, Inc. (CLVS)
Stock Price:
$6.14 USD
0.35 (6.04%)
Updated Aug 3, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
540.26M |
| Revenue (ttm) |
152.45M |
| Net Income (ttm) |
-413.34M |
| Shares Out |
87.99M |
| EPS (ttm) |
-7.06 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 3, 2020 |
| Last Price |
$6.14 |
| Previous Close |
$5.79 |
| Change ($) |
0.35 |
| Change (%) |
6.04% |
| Day's Open |
5.83 |
| Day's Range |
5.78 - 6.15 |
| Day's Volume |
3,583,072 |
| 52-Week Range |
2.93 - 17.37 |
More Stats
| Market Cap |
540.26M |
| Enterprise Value |
922.35M |
| Earnings Date (est) |
Aug 6, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
87.99M |
| Float |
69.72M |
| EPS (basic) |
-7.19 |
| EPS (diluted) |
-7.06 |
| FCF / Share |
-4.32 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
30.24M |
| Short Ratio |
7.74 |
| Short % of Float |
38.20% |
| Beta |
2.48 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
3.54 |
| PB Ratio |
n/a |
| Revenue |
152.45M |
| Operating Income |
-373.56M |
| Net Income |
-413.34M |
| Free Cash Flow |
-309.48M |
| Net Cash |
-382.09M |
| Net Cash / Share |
-4.34 |
| Gross Margin |
74.17% |
| Operating Margin |
-245.03% |
| Profit Margin |
-271.10% |
| FCF Margin |
-203.00% |
| ROA |
-32.83% |
| ROE |
-547.55% |
| ROIC |
-41.80% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (10)
| Buy |
3 |
| Overweight |
0 |
| Hold |
4 |
| Underweight |
1 |
| Sell |
2 |
Analyst Consensus: Overweight
Price Target
$13.62*
(121.82% upside)
Low
4.00
Current: $6.14
High
32.00
Target: 13.62
*Average 12-month price target from 8 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 143 | 95.39 | 55.51 | 0.08 | - | 13.63 | - | - | - | - |
| Revenue Growth | 49.92% | 71.84% | 71067.95% | - | - | - | - | - | - | - |
| Gross Profit | 108 | 73.31 | 43.77 | 0.01 | - | 13.63 | - | - | - | - |
| Operating Income | -377 | -334 | -238 | -398 | -401 | -158 | -83.36 | -73.78 | -54.59 | -38.63 |
| Net Income | -400 | -368 | -346 | -349 | -353 | -160 | -84.53 | -73.98 | -55.57 | -37.83 |
| Shares Outstanding | 53.87 | 52.07 | 47.05 | 38.48 | 36.03 | 33.89 | 28.67 | 24.92 | 3.85 | 1.33 |
| Earnings Per Share | -7.43 | -7.07 | -7.36 | -9.07 | -9.79 | -4.72 | -2.95 | -2.97 | -14.42 | -28.55 |
| Operating Cash Flow | -324 | -366 | -261 | -267 | -253 | -117 | -71.71 | -65.38 | -39.83 | -34.01 |
| Capital Expenditures | -3.02 | -9.24 | -3.00 | -0.70 | -3.04 | -2.29 | -0.12 | -1.06 | -0.45 | -0.77 |
| Free Cash Flow | -327 | -375 | -264 | -267 | -256 | -119 | -71.83 | -66.44 | -40.27 | -34.78 |
| Cash & Equivalents | 297 | 520 | 564 | 266 | 529 | 483 | 323 | 144 | 140 | 22.30 |
| Total Debt | 715 | 575 | 282 | 281 | 280 | 279 | - | - | - | - |
| Net Cash / Debt | -418 | -55.32 | 281 | -14.94 | 249 | 204 | 323 | 144 | 140 | 22.30 |
| Assets | 670 | 864 | 735 | 365 | 713 | 777 | 650 | 146 | 143 | 26.20 |
| Liabilities | 844 | 717 | 368 | 368 | 413 | 446 | 152 | 12.50 | 11.65 | 80.95 |
| Book Value | -174 | 146 | 368 | -3.63 | 301 | 332 | 498 | 133 | 132 | -54.75 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Clovis Oncology, Inc. |
| Country |
United States |
| Employees |
484 |
| CEO |
Patrick J. Mahaffy |
Stock Information
| Ticker Symbol |
CLVS |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: CLVS |
| IPO Date |
November 16, 2011 |
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. The company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It also provides lucitanib, an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors, platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors. The company distributes its products primarily through specialty distributors and pharmacy providers to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, and Advenchen Laboratories LLC; collaboration agreements with Bristol-Myers Squibb Company and Myriad Genetics, Inc.; and a partnership with Foundation Medicine, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.